Individually Dose-adjusted FEC Compared to Standard FEC as Adjuvant Chemotherapy for Node Positive or High-risk Node Negative Breast Cancer
Condition: Breast Cancer Intervention: Drug: 5-FU, epirubicin and cyclophosphamide Sponsors: Henrik Lindman; Scandinavian Breast Cancer Group; Danish Breast Cancer Group; Swedish Cancer Society; Swedish Breast Cancer Association; Uppsala University Oncology Department Trust; Pharmacia Pharmaceutical Company; Swedish Breast Cancer Group Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials